![Adipogen/Carfilzomib [PR-171]/AG-CR1-3669-M025/25 mg](https://www.ebiomall.cn/images/adipogen/ag-cr1-3669.png)
Adipogen/Carfilzomib [PR-171]/AG-CR1-3669-M025/25 mg
商品编号：
AG-CR1-3669-M025
品牌：
Adipogen Inc
市场价：
¥5400.00
美元价：
3240.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | (αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzeNEButanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide |
| ProductType | Chemical |
| Properties | |
| Formula | C40H57N5O7 |
| MW | 719.9 |
| CAS | 868540-17-4 |
| PurityChemicals | ≥98% |
| Appearance | Whitesolid. |
| Solubility | SolubleinDMSO(30mg/ml)orEtOH(20mg/ml).Poorlysolubleinaqueousbuffers. |
| OtherProductData | Note:Warmingandsonicationmayberequiredwhendissolvingthecompoundinthesolventofchoice.Stocksolutionsarestableforatleast1monthwhenstoredat-20°C. |
| InChiKey | BLMPQMFVWMYDKT-NZTKNTHTSA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Keepcoolanddry. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- PotentandirreversIBLesecond-generationpeptideepoxyketoneclassproteasomeinhibitor.Syntheticanalogofthemicrobialproductepoxomicin(Prod.No.AG-CN2-0422).
- Targetsthechymotrypsin-likeβ5subunitoftheconstitutive20Sproteasome(IC50=5.2nM)andtheβ5isubunit[LMP7]ofthe20Simmunoproteasome(IC50=14nM),withminimalcross-reactivitytootherproteases.
- Displaysequalpotencybutgreaterselectivityforthechymotrypsin-likeactivityoftheproteasomecomparedtobortezomib(Prod.No.AG-CR1-3602).
- Anticancercompoundeffectiveagainstmultiplemyelomainvivo.
- Invitro,inducescellcyclearrestandapoptosisinhumancancercelllinesincludingmultiplemyeloma,lymphomaandvarioussolidtumors(IC50s=2.4-20nM).
ProductReferences
- AntitumoractivityofPR-171,anovelirreversibleinhibitoroftheproteasome:S.D.Demo,etal.;CancerRes.67,6383(2007)
- Potentactivityofcarfilzomib,anovel,irreversibleinhibitoroftheubiquitin-proteasomepathway,againstpreclinicalmodelsofmultiplemyeloma:D.J.Kuhn,etal.;Blood110,3281(2007)
- TheproteasomeinhibitorsbortezomibandPR-171haveantiproliferativeandproapoptoticeffectsonprimaryhumanacutemyeloidleukaemiacells:C.Stapnes,etal.;Br.J.Haematol.136,814(2007)
- Carfilzomibcaninducetumorcelldeaththroughselectiveinhibitionofthechymotrypsin-likeactivityoftheproteasome:F.Parlati,etal.;Blood114,3439(2009)
- Secondgenerationproteasomeinhibitors:carfilzomibandimmunoproteasome-specificinhibitors(IPSIs):D.J.Kuhn,etal.;Curr.CancerDrugTargets11,285(2011)(Review)
- Carfilzomib-dependentselectiveinhibitionofthechymotrypsin-likeactivityoftheproteasomeleadstoantitumoractivityinWaldenstrom"sMacroglobulinemia:A.Sacco,etal.;Clin.CancerRes.17,1753(2011)
- Nonproteasomaltargetsoftheproteasomeinhibitorsbortezomibandcarfilzomib:alinktoclinicaladverseevents:S.Arastu-Kapur,etal.;Clin.CancerRes.17,2734(2011)
- Carfilzomib:anovelsecond-generationproteasomeinhibitor:M.L.Khan&A.K.Stewart;FutureOncol.7,607(2011)
- ThenextgenerationproteasomeinhibitorscarfilzomibandoprozomibactivateprosurvivalautophagyviainductionoftheunfoldedproteinresponseandATF4:Y.Zang,etal.;Autophagy8,1873(2012)
- Fromepoxomicintocarfilzomib:chemistry,BIOLOGy,andmedicaloutcomes:K.B.Kim&C.M.Crews;Nat.Prod.Rep.30,600(2013)
- Invitroandinvivotherapeuticefficacyofcarfilzomibinmantlecelllymphoma:targetingtheimmunoproteasome:L.Zhang,etal.;Mol.CancerTher.12,2494(2013)
- Carfilzomibforthetreatmentofpatientswithrelapsedand/orrefractorymultiplemyeloma:A.K.Stewart;FutureOncol.11,2121(2015)
- CarfilzomibInhibitsConstitutiveNF-κBActivationinMantleCellLymphomaBCellsandLeadstotheInductionofApoptosis:Y.L.Zhang,etal.;ActaHaematol.137,106(2017)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
